Literature DB >> 3624659

Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis.

P R Eisenberg, L A Sherman, A S Jaffe.   

Abstract

Elevated levels of fibrinopeptide A, a marker of thrombin activity associated with acute myocardial infarction, have been found to decrease after administration of streptokinase when reperfusion occurs. In contrast, in patients without reperfusion and those with reocclusion after streptokinase therapy, fibrinopeptide A remains elevated. In the present study early serial measurements of fibrinopeptide A were used to further characterize this paradoxic increase in thrombin activity after streptokinase and to characterize its response to heparin. In 19 patients with acute myocardial infarction fibrinopeptide A was elevated to 82.3 +/- 43.5 ng/ml (mean +/- SE) before therapy. Thirty minutes after the initiation of streptokinase, fibrinopeptide A increased to 300.1 +/- 117.4 ng/ml (p less than 0.01), consistent with extensive thrombin activity. Fibrinopeptide A remained elevated until 15 minutes after a heparin bolus injection when levels decreased to 15% of the poststreptokinase value (49.2 +/- 13.3 ng/ml) (p less than 0.001). These data document a prompt paradoxic increase in thrombin activity after administration of streptokinase that may be responsible for failure of therapy in some patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3624659     DOI: 10.1016/s0735-1097(87)80194-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  24 in total

Review 1.  Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction.

Authors:  M P Hudson; A B Greenbaum; R A Harrington; E M Ohman
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

2.  Guidelines for the Management of Patients with Acute Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998       Impact factor: 2.300

Review 3.  Advances in thrombolytic therapy.

Authors:  M Verstraete
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

4.  Is thrombolysis alone the best therapy for acute myocardial infarction? Current status and emerging strategies.

Authors:  P Golino; J T Willerson
Journal:  Tex Heart Inst J       Date:  1991

5.  Physicians' Use of Heparin Following Thrombolytic Therapy: An International Perspective.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

6.  Adjunctive Therapy with an Antithrombotic Drug Can Prevent Reocclusion and Induce Residual Thrombus Reduction After Percutaneous Transcatheter Angioplasty of the Thrombotic Lesions.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

7.  Issues Regarding the Use of Heparin Following Streptokinase Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

8.  Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase.

Authors:  Volker Pönitz; David Pritchard; Heidi Grundt; Dennis Winston T Nilsen
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

9.  Correlation between clinical course and quantitative analysis of the ischemia related artery in patients with unstable angina pectoris, refractory to medical treatment. Results of two randomized trials. The European Cooperative Study Group.

Authors:  M J van den Brand; A van Miltenburg; M J de Boer; L R van der Wieken; P J de Feyter; M L Simoons
Journal:  Int J Card Imaging       Date:  1994-09

10.  Comparative effects of anti-platelet agents as adjuncts to tissue plasminogen activator in a dog model of occlusive coronary thrombosis.

Authors:  S J McAuliffe; J A Moors; H B Jones
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.